Covalent conjugation of AZD8055 with unsaturated fatty acids for the development of mTOR nanoblockers: increasing the therapeutic efficacy of hepatocellular carcinoma treatment

EBioMedicine. 2024 May:103:105113. doi: 10.1016/j.ebiom.2024.105113. Epub 2024 Apr 6.

Authors

Wing Ki Chau¹, Terence Kin Wah Lee²

Affiliations

¹ Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong.
² Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong; State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Hong Kong. Electronic address: terence.kw.lee@polyu.edu.hk.

No abstract available

Publication types

Letter

MeSH terms

Animals
Antineoplastic Agents / chemistry
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / metabolism
Carcinoma, Hepatocellular* / pathology
Cell Line, Tumor
Fatty Acids, Unsaturated* / chemistry
Fatty Acids, Unsaturated* / metabolism
Fatty Acids, Unsaturated* / pharmacology
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / metabolism
Liver Neoplasms* / pathology
Morpholines* / chemistry
Morpholines* / pharmacology
TOR Serine-Threonine Kinases* / metabolism

Substances

Antineoplastic Agents
Fatty Acids, Unsaturated
TOR Serine-Threonine Kinases
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
Morpholines